Chakma Justin 4
4 · ARS Pharmaceuticals, Inc. · Filed Nov 14, 2025
Insider Transaction Report
Form 4
Chakma Justin
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-12$0.84/sh+30,000$25,200→ 166,380 total - Sale
Common Stock
2025-11-12$8.91/sh−30,000$267,357→ 136,380 total - Sale
Common Stock
2025-11-12$8.86/sh−136,380$1,208,790→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-12−30,000→ 89,047 totalExercise: $0.84Exp: 2029-07-04→ Common Stock (30,000 underlying)
Footnotes (3)
- [F1]The weighted average sale price for the transaction reported was $8.9119, and the range of prices was between $8.87 and $8.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F2]The weighted average sale price for the transaction reported was $8.8634, and the range of prices was between $8.62 and $9.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F3]Immediately exercisable.